<DOC>
	<DOCNO>NCT01450605</DOCNO>
	<brief_summary>The purpose post-marketing surveillance investigate confirm type incidence newly identify adverse event factor affect safety efficacy Reyataz® regulatory authority manage marketing approval properly</brief_summary>
	<brief_title>Korean Post-marketing Surveillance Reyataz®</brief_title>
	<detailed_description />
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Patients ≥ 13 year age HIV1 Reyataz® treatment time enrollment never participate study previously initiate Reyataz® treatment first time reallife condition register indication ( ) require KFDA According Warning/Caution local label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>